| Document |
Document Title |
|
WO/2016/155578A1 |
The present invention relates to a crystal form I of Dapagliflozin which is a medicine for treating type II diabetes, and a preparation method therefor. The crystal form I is characterized in that an x-ray powder diffraction pattern has ...
|
|
WO/2016/161269A1 |
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...
|
|
WO/2016/151066A1 |
The present invention relates to compounds derived from deoxy fucose. These compounds are useful as lectin inhibitors, especially as inhibitors of LecB. The invention also relates to pharmaceutical compositions comprising these compounds...
|
|
WO/2016/151989A1 |
The present invention can provide novel C-glycoside derivatives which are biologically important under high stereoselective, mild, atom economical condition.
|
|
WO/2016/147197A1 |
The present invention discloses the process for preparation of (2S,3R,4R,5S,6R)-2-[4- chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro
-2H-pyran-3,4,5-triol and its amorphous form.
|
|
WO/2016/138821A1 |
The present invention provides compounds of the Formula (1), wherein R, R1-R3 are as described herein; methods of treating patients for diabetes using the compounds, and processes for preparing the compounds.
|
|
WO/2016/139351A1 |
The invention relates to compounds of Formula (I) and their use as selective dipeptidyl peptidase I inhibitors, as well as pharmaceutical compositions comprising said compounds, and methods of treatment involving said compounds.
|
|
WO/2016/138631A1 |
Compounds of formula I and the pharmaceutically acceptable salt thereof are disclosed, wherein R is selected from the group consisting of O and NH, R 1 is selected from the group consisting of CF 3, OCF 3 and Cl.
|
|
WO/2016/139338A1 |
The present invention relates to a method for producing tetrahydropyranyl esters from the corresponding 4-hydroxy-tetrahydropyran compounds by reaction with a ketene compound.
|
|
WO/2016/131098A1 |
ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in ...
|
|
WO/2016/128422A1 |
The present invention relates to an improved process of producing cyclo-dehydrolinalool by the cyclization of the compound of formula (II).
|
|
WO/2016/129490A1 |
Provided is a polar compound having high chemical stability, high ability to align liquid crystal molecules, and high solubility in a liquid crystal composition, and which has a large voltage holding ratio when used in a liquid crystal d...
|
|
WO/2016/130527A1 |
Disclosed herein are substituted cyclic ether monomers, polymers, and drug conjugates thereof, which are useful for the treatment of diseases and conditions of the oral cavity. In particular, disclosed herein are monomers of Formula (I),...
|
|
WO/2016/128995A1 |
The present invention DISCLOSES a novel process for preparing sodium glucose transporters 2 (SGLT2) inhibitor compounds of Formula IX. Wherein, R is halogen, alkyl or alkoxy group; and Ar is aryl group, substituted or unsustituted monocy...
|
|
WO/2016/128423A1 |
The present invention relates to an improved process of producing cyclo-dehydrolinalool.
|
|
WO/2016/120879A1 |
The present invention provides compounds comprising fused tricyclic backbone structure and processes for their preparation. The invention further provides compounds and compositions useful in the treatment of pain and any type of disorde...
|
|
WO/2016/109470A1 |
Small molecule stimulators of steroid receptor coactivator (SRC) family proteins are provided, as well as methods for their use in treating or preventing cancer. Also provided are methods for stimulating SRC family proteins in a cell.
|
|
WO/2016/098016A1 |
The present application relates to the process for the preparation of SGLT2 inhibitors, further covers a process for the preparation of Canagliflozin, preparation of amorphous form of Canagliflozin and solid dispersion of Canagliflozin.
|
|
WO/2016/097389A1 |
The invention relates to benzenesulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan rece...
|
|
WO/2016/082510A1 |
The present invention relates to a liquid crystal compound of a structure as represented by formula I, where R is selected from H and alkyls or alkoxies that are either unsubstituted or have one or multiple H being substituted by halogen...
|
|
WO/2016/082511A1 |
The present invention relates to a liquid crystal compound of a structure as represented by formula I, where R is selected from H and alkyls or alkoxies that are either unsubstituted or have one or multiple H being substituted by halogen...
|
|
WO/2016/083517A1 |
The invention relates to a compound of formula (I), in which R' represents a hydrogen atom or an acyl group having between 2 and 18 carbon atoms, and R" represents a hydrogen atom or an alkyl group having between 1 and 18 carbon atoms, a...
|
|
WO/2016/085392A1 |
The present invention relates to bis(sulfonamide) compounds and pharmaceutically acceptable salts thereof. The present invention also relates to pharmaceutical compositions comprising these compounds and to their use as a medicament for ...
|
|
WO/2016/082583A1 |
The present invention relates to kinetic resolution of asymmetric catalytic hydrogenation of racemic δ-hydroxy ester and an application thereof. An iridium catalyst of a chiral spiropyridine amidocyanogen phosphin ligand is used; in a c...
|
|
WO/2016/085987A1 |
The invention relates to a process comprising reacting mevalonic acid, or a solution comprising mevalonic acid, to yield a first product or first product mixture, optionally in the presence of a solid catalyst and/or at elevated temperat...
|
|
WO/2016/080626A2 |
Described are prodrug conjugates that release a chemotherapeutic agent upon activation by caspase, and methods using such prodrug conjugates to induce apoptosis, amplify apoptosis, and treat cancer.
|
|
WO/2016/066555A1 |
There is provided polymorphs of ferric maltol. Such forms may be useful in the treatment of iron deficiency with or without anaemia, such as iron deficiency anaemia.
|
|
WO/2016/063990A1 |
The present invention relates to a compound represented by general formula (1). (The definition of each group in the formula is as described in the specification.) The compound is useful as a prophylactic and/or therapeutic agent for KCN...
|
|
WO/2016/059648A1 |
The present invention discloses a process for synthesis of chiral 2,4-disubstituted- tetrahydropyran-4-ol and its derivatives having a general formal (I) comprising of asymmetric reaction of an aliphatic aldehyde and a homoallylic alcoho...
|
|
WO/2016/061393A1 |
Monomethyl and monoethyl fumarate prodrugs, pharmaceutical compositions comprising the monomethyl and monoethyl fumarate prodrugs, and methods of using monomethyl and monoethyl fumarate prodrugs and pharmaceutical compositions for treati...
|
|
WO/2016/057322A1 |
Provided herein are deuterated compounds and compositions useful in increasing PPAR5 activity. The compounds and compositions provided herein are useful for the treatment of PPAR5 related diseases (e.g., muscular diseases, vascular disea...
|
|
WO/2016/055404A1 |
The present invention relates to a process for preparation of intermediates (Z,2E)-5-hydroxy-2-methoxyimino-N-methyl-pent-3-enamides from 4-substituted 5-meth-oxyimino-2H-pyran-6-ones and their processing for example to (Z)-5-cyclyloxy-2...
|
|
WO/2016/052069A1 |
Provided is a thiol compound represented by formula (1); (HS-R1-M1-)nL1 (1). In formula (1), L1 denotes an n-valent organic linking group, n denotes an integer between 3 and 15, M1 denotes -O-, -S-, -N(R2)-, -C(=O)-, -C(=O)-O-, -O-C(=O)-...
|
|
WO/2016/046360A1 |
The invention relates to the use of isomerically pure or highly isomer-enriched cis- or trans-(2-isobutyl-4-methyl-tetrahydropyran-4-yl)acetate as aroma chemicals. The invention further relates to a method for producing isomerically pure...
|
|
WO/2016/034559A1 |
The present invention relates to a method for preparing marmycin A and analogues thereof, to novel marmycin A analogues, and also to the use of these compounds as an organelle marker and in pharmacy, in particular as antibiotics, antican...
|
|
WO/2016/034963A1 |
Compounds of the formula (I) (I), wherein X is O, S, a direct bond or CR16R17; Y is O or S; R1, R2, R3, R4, R5, R6, R7 and R8 for example are hydrogen, halogen, C1-C4alkyl, or a group of formula (II) or (III) (II) (III) provided that eit...
|
|
WO/2016/032148A2 |
The present invention relates to kartogenin-conjugated chitosan particles with an improved extended release property and biocompatibility. Effects of increases in biocompatibility, chondrogenic differentiation efficiency and staying time...
|
|
WO/2016/028959A1 |
Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V) and/or a salt thereof, wherein R1 is OH or OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as ...
|
|
WO/2016/019907A1 |
According to embodiments of present disclosure, a method to produce a compound of Formula (19) is provided. Using this method, the compound of Formula (19) may be produced effectively.
|
|
WO/2016/015596A1 |
A process of preparing 2, 3-disubstituted-5-oxopyran compounds, comprising cyclizing a compound in the presence of a base and an organic solvent is provided.
|
|
WO/2016/016178A1 |
The invention relates to the use of a CXCR2 antagonist for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN).
|
|
WO/2016/001396A1 |
The invention relates to cyclic derivatives of epoxyprostanoids having a lactone ring, in particular to compound (9) and related compounds, and their use as therapeutic agents in the treatment of bacterial infections and inflammation.
|
|
WO/2015/197468A1 |
The present invention relates to a compound of formula (I) wherein: R1 is C1-C3alkoxy, C1-C2alkoxy-C1-C3alkoxy, C1-C2fluoroalkoxy, ethyl, n-propyl, n-butyl, cyclopropyl or ethynyl; R2 is hydrogen, ethyl, n-propyl, cyclopropyl, vinyl, eth...
|
|
WO/2015/199167A1 |
Provided is a method for producing a substituted spiropyrido[1,2-a]pyrazine derivative, or a salt thereof, that are useful as anti-HIV agents. Also provided is a production intermediate. Compound [VIII] is obtained by reacting compound [...
|
|
WO/2015/192701A1 |
An amino pyranoid ring derivative represented by general formula (I), or stereoisomers, pharmaceutically acceptable salts, prodrugs, pharmaceutical compositions containing the derivative and medicinal use thereof in preparing dipeptidyl ...
|
|
WO/2015/187040A1 |
The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or...
|
|
WO/2015/181186A1 |
The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, and their use in treating or preventing diseases and conditions mediated by the CXCR2 receptor. In addition, the invention relates to compositions con...
|
|
WO/2015/177083A1 |
The invention belongs to the fields of pharmaceutical industry, and particularly to an improved stereoselective synthesis of intermediate compounds for the preparation of gliflozins, for example canagliflozin or structurally similar glif...
|
|
WO/2015/174695A1 |
The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate...
|
|
WO/2015/170635A1 |
This non-ionic surfactant is characterized by being represented by general formula (1). (In general formula (1), R1 is a chain alkyl group optionally containing a branched chain, R2 is a hydrogen atom or an alkyl group, and R3 is a hydro...
|
